ProCE Banner Activity

Adult ADHD: What’s New? Innovations in Management of Adult ADHD

Slideset Download
This presentation reviews the efficacy, mechanism of action, and potential side effects associated with new treatments for adults with ADHD; and strategies, either currently approved or in development, to improve executive function.

Released: February 21, 2022

Expiration: February 20, 2023

No longer available for credit.

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor
Washington University
President
Midwest Research Group
President Elect
American Professional Society for ADHD and Related Disorders
St. Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant provided by

Supernus Pharmaceuticals Inc

Faculty Disclosure

Primary Author

Greg W. Mattingly, MD

Associate Clinical Professor
Washington University
President
Midwest Research Group
President Elect
American Professional Society for ADHD and Related Disorders
St. Louis, Missouri

Greg Mattingly, MD, has disclosed that he has received consulting fees from AbbVie, Acadia, Alkermes, Axsome, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Otsuka, Redax, Roche, Rhodes, Sage, Shire, Sunovion, Supernus, Takeda, Teva, and Trispharma; funds for research support from AbbVie, Acadia, Alkermes, Avanir, Axsome, Boehringer Ingelheim, Emalex, Janssen, Medgenics, NLS-1 Pharma AG, Redax, Roche, Sage, Shire, Sunovion, Supernus, Takeda, and Teva; and fees for non-CME/CE services from AbbVie, Alkermes, Eisai, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, and Trispharma.